Anthony Lowell
Division of Hematology/Oncology, Louisiana State University, New Orleans, LA, USA.
Semin Oncol Nurs. 2003 Nov;19(4 Suppl 3):17-21. doi: 10.1053/j.soncn.2003.09.010.
To describe possible new strategies for the prevention of CTID.
Abstracts presented at oncology meetings, primary and secondary literature, trial protocols, and clinical experience.
Patients who have experienced an episode of diarrhea are at high risk for developing diarrhea with additional cycles of chemotherapy or radiation. One preventive strategy that holds out promise is the use of octreotide LAR as prophylaxis. This strategy should be considered for patients with a prior cycle complicated by persistent (lasting more than 48 hours) diarrhea of any severity, or by diarrhea of grades 3 and higher.
With preventive intervention and aggressive management of breakthrough symptoms, CTID may no longer pose a significant threat to patient comfort and well-being.
描述预防化疗引起的腹泻(CTID)的可能新策略。
肿瘤学会议上发表的摘要、一级和二级文献、试验方案以及临床经验。
经历过一次腹泻发作的患者在接受额外周期的化疗或放疗时发生腹泻的风险很高。一种有前景的预防策略是使用长效奥曲肽作为预防措施。对于之前周期出现任何严重程度的持续性(持续超过48小时)腹泻或3级及以上腹泻的患者,应考虑这一策略。
通过预防性干预和对突破性症状的积极管理,CTID可能不再对患者的舒适度和健康构成重大威胁。